Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1 1

Status

Unknown 3Completed 1

Sponsor Class

OTHER 11INDUSTRY 4OTHER_GOV 3

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 4Breast 1

Conditions

Stomach Neoplasms 12Neoplasms 7Carcinoma, Non-Small-Cell Lung 5Ovarian Neoplasms 4Triple Negative Breast Neoplasms 3Neoplasm Metastasis 3Sarcoma 2Colorectal Neoplasms 2Carcinoma, Hepatocellular 2Advanced Solid Tumor 2Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation 1Solid Tumor, Adult 1Small Cell Lung Carcinoma 1Recurrence 1Pancreatic Neoplasms 1PD-L1 Positive Non-small Cell Lung Cancer 1NSCLC 1Metastatic Castration Resistant Prostate Cancer 1Malignant Neoplasms of Digestive Organs 1Fallopian Tube Neoplasms 1Cytochrome P450 Interaction 1Carcinoma, Adenoid Cystic 1Breast Neoplasms 1Advanced Primary Liver Cancer 1Advanced Cancer 1

Interventions

Paclitaxel 113Carboplatin 99Bevacizumab 59pembrolizumab 56liposomal doxorubicin 56Gemcitabine 42olaparib 39Topotecan 33niraparib 29Nivolumab 21Cisplatin 21Doxorubicin 17Cyclophosphamide 171-dodecylpyridoxal 16Drug Therapy 15Docetaxel 15avelumab 13Fulvestrant 11oregovomab 10Oxaliplatin 10rucaparib 9fludarabine 9Injections 9Fluorouracil 9veliparib 8mirvetuximab soravtansine 8atezolizumab 8Cetuximab 8fluzoparib 7cemiplimab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Ovarian Neoplasms × apatinib × Clear all
NCT03075462 2022-07-01

A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Completed
98 enrolled
BreastGynecologic

Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT04229615 2022-04-25

A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Unknown
690 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04383977 2020-05-12

Apatinib and Etoposide Capsule Versus Apatinib in Patients With Platinum Resistant Ovarian Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Unknown
54 enrolled
Gynecologic

Ovarian Neoplasms

NCT04000295 2019-10-08

Apatinib and Etoposide Capsule Versus Weekly Paclitaxel in Patients With Platinum Resistant Ovarian Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Unknown
280 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡